VIJAY NAMBI to Anticholesteremic Agents
This is a "connection" page, showing publications VIJAY NAMBI has written about Anticholesteremic Agents.
Connection Strength
1.592
-
LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon. J Am Coll Cardiol. 2024 02 13; 83(6):665-668.
Score: 0.680
-
Advances in the management of dyslipidemia. Curr Opin Cardiol. 2017 Jul; 32(4):348-355.
Score: 0.430
-
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
Score: 0.180
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.120
-
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
Score: 0.093
-
Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
Score: 0.058
-
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
Score: 0.032